Michael C. Sheppard

Michael C. Sheppard's AcademicInfluence.com Rankings

Michael C. Sheppard

Philosophy

#8135

World Rank

#11459

Historical Rank

Logic

#5165

World Rank

#6540

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Michael C. Sheppard's Degrees

PhD Biomedical Sciences Stanford University

Why Is Michael C. Sheppard Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael C. Sheppard's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study (2001) (682)
Prevalence and follow‐up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom (1991) (589)
Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. (2006) (510)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. (2000) (499)
Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. (2001) (459)
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. (2004) (328)
Mortality in patients with pituitary disease. (2010) (321)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study (2014) (312)
Mortality after the treatment of hyperthyroidism with radioactive iodine. (1998) (284)
Age and gender predict the outcome of treatment for Graves' hyperthyroidism. (2000) (268)
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene (1996) (252)
Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. (2001) (243)
Modulation of 11β‐Hydroxysteroid Dehydrogenase Isozymes by Proinflammatory Cytokines in Osteoblasts: An Autocrine Switch from Glucocorticoid Inactivation to Activation (2001) (240)
Consensus statement: medical management of acromegaly. (2005) (227)
Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study (1999) (215)
Long-term thyroxine treatment and bone mineral density (1992) (210)
Association between serum free thyroxine concentration and atrial fibrillation. (2007) (204)
Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. (2002) (200)
Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. (1979) (195)
The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. (1999) (178)
Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. (1999) (170)
A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. (2010) (168)
Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. (1993) (167)
Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects (2006) (167)
Modulation of 11β-Hydroxysteroid Dehydrogenase Isozymes by Growth Hormone and Insulin-Like Growth Factor: In Vivo and In Vitro Studies1 (1999) (156)
Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor‐2 (FGF‐2) in human pituitary adenomas: relationships to clinical tumour behaviour (2003) (156)
Thyroid function and mortality in patients treated for hyperthyroidism. (2005) (155)
ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. (2009) (153)
Clinical, quality of life, and economic value of acromegaly disease control (2011) (153)
Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. (1995) (151)
Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. (1996) (148)
Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. (1998) (148)
Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. (1993) (145)
Long‐term follow‐up of treatment of thyrotoxicosis by three different methods (1991) (137)
Growth hormone and its disorders (2006) (135)
Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. (2007) (133)
Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. (2003) (131)
Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly (1998) (127)
Circulating lipids and minor abnormalities of thyroid function (1992) (123)
Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. (1996) (123)
Diagnosis and treatment of acromegaly complications (2003) (117)
Tissue localization of 11β-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor (1992) (117)
Weight gain following treatment of hyperthyroidism (2001) (116)
Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotype: interactions among T3, vitamin D3, and retinoid signaling. (1994) (116)
Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. (2006) (112)
Long‐Acting Octreotide and Prolonged‐Release Lanreotide Formulations Have Different Pharmacokinetic Profiles (2005) (112)
Life expectancy following surgery for pituitary tumours (1999) (111)
Thyroxine replacement therapy and circulating lipid concentrations (1993) (107)
STIMULATION BY GROWTH HORMONE OF SOMATOSTATIN RELEASE FROM THE RAT HYPOTHALAMUS IN VITRO (1978) (107)
Relation between serum interleukin‐6 and thyroid hormone concentrations in 270 hospital in‐patients with non‐thyroidal illness (1996) (103)
Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. (2002) (94)
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults (2008) (92)
Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? (2002) (89)
The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly (1995) (89)
Thyroid status in patients after acute myocardial infarction. (1984) (85)
Sandostatin LAR®: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients (1995) (85)
Successful Treatment of Amiodarone-Induced Thyrotoxicosis (2002) (84)
Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement (1996) (84)
Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis (1994) (83)
Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. (1993) (81)
Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. (1994) (81)
Giant invasive prolactinoma: a case report and review of nine further cases. (1990) (80)
Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. (1999) (79)
Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. (1994) (79)
Radiotherapy for non-function pituitary tumours. (1998) (79)
AMIODARONE AND THYROID HORMONE ACTION JAYNE A. (1985) (77)
Primary medical therapy for acromegaly (2003) (77)
Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism (2009) (76)
Thyroid nodules in the population living around Chernobyl. (1992) (75)
Efficacy of Sandostatin® LAR® (long‐acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy (2004) (74)
THYROID HORMONE RECEPTOR EXPRESSION IN THE "SICK EUTHYROID" SYNDROME (1989) (74)
Basic fibroblast growth factor affects DNA synthesis and cell function and activates multiple signalling pathways in rat thyroid FRTL-5 and pituitary GH3 cells. (1990) (71)
SERIAL SERUM THYROGLOBULIN MEASUREMENTS IN THE MANAGEMENT OF DIFFERENTIATED THYROID CARCINOMA (1985) (71)
Does acromegaly enhance mortality? (2008) (71)
The Renal Expression of Transforming Growth Factor-β Isoforms and Their Receptors in Acute and Chronic Experimental Diabetes in Rats. (2000) (69)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study (2014) (68)
Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. (2009) (66)
Expression of fibroblast growth factors in thyroid cancer. (1995) (64)
Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism (1995) (64)
Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. (1998) (63)
Lack of association between polymorphism of the thyrotropin receptor gene and Graves' disease in United Kingdom and Hong Kong Chinese patients: case control and family-based studies. (1998) (60)
Fine needle aspiration cytology in diffuse or multinodular goitre compared with solitary thyroid nodules. (1993) (58)
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study (2016) (57)
Expression and function of thyroid hormone receptor variants in normal and chronically diseased human liver. (1996) (56)
Functional human thyroid cells and their insulin-like growth factor-binding proteins: regulation by thyrotropin, cyclic 3',5' adenosine monophosphate, and growth factors. (1996) (55)
Abnormal expression of 11β-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation (2003) (54)
Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. (1997) (54)
Characterization of Aromatase and 17β‐Hydroxysteroid Dehydrogenase Expression in Rat Osteoblastic Cells (1998) (54)
Effect of Mg2+ on Na+-Dependent Inositol Transport: Role for Mg2+ in Etiology of Diabetic Complications (1992) (53)
Differential growth response to oestrogen of premalignant and malignant colonic cell lines. (1994) (53)
Levothyroxine treatment and occurrence of fracture of the hip. (2002) (52)
Retinoids modify regulation of endogenous gene expression by vitamin D3 and thyroid hormone in three osteosarcoma cell lines. (1995) (51)
Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours (2002) (51)
Assessing the hypothalamo-pituitary-adrenal axis in patients on long-term glucocorticoid therapy: the short synacthen versus the insulin tolerance test. (1995) (50)
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. (1999) (50)
11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease. (1993) (50)
Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. (1995) (49)
The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. (2000) (49)
Tissue and Serum Somatostatin-like Immunoreactivity in Fed, 15-h-fasted, and 72-h-fasted Rats (1979) (48)
HLA class II gene polymorphism contributes little to Hashimoto's thyroiditis (1992) (48)
Changes in the immunohistochemical localisation of fibroblast growth factor-2, transforming growth factor-beta 1 and thrombospondin-1 are associated with early angiogenic events in the hyperplastic rat thyroid. (1996) (47)
Gender, clinical findings, and serum thyrotropin measurements in the prediction of thyroid neoplasia in 1005 patients presenting with thyroid enlargement and investigated by fine-needle aspiration cytology. (1999) (47)
Potassium stimulated calcium dependent release of immunoreactive somatostatin from incubated rat hypothalamus (1978) (46)
Heart rate variability and turbulence in hyperthyroidism before, during, and after treatment. (2004) (46)
Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer. (1997) (46)
An audit of management of differentiated thyroid cancer in specialist and non‐specialist clinic settings (2001) (44)
Medical therapy in acromegaly (2011) (44)
Clinical and biochemical response following withdrawal of a long‐acting, depot injection form of octreotide (Sandostatin‐LAR®) (1999) (42)
Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? (1992) (40)
Novel aspects of hormone action: Intracellular ligand supply and its control by a series of tissue specific enzymes (1992) (40)
Tri-iodothyronine and phenytoin reduce prolactin messenger RNA levels in cultured rat pituitary cells. (1986) (40)
Expression of oestrogen receptor and oestrogen‐inducible genes ps2 and erd5 in large bowel mucosa and cancer (1998) (40)
Localization of renal 11 beta-dehydrogenase by in situ hybridization: autocrine not paracrine protector of the mineralocorticoid receptor. (1991) (40)
Role of growth factors and estrogen as modulators of growth, differentiation, and expression of gonadotropin subunit genes in primary cultured sheep pituitary cells. (1994) (39)
Serum thyroglobulin measurements in thyroid cancer: evaluation of‘false’ positive results (1991) (39)
Serum free thyroxine and free triiodothyronine concentrations in pregnancy. (1983) (39)
11-Beta-hydroxysteroid dehydrogenase activity and gene expression in the hypertensive Bianchi—Milan rat (1993) (39)
Tie-2 is expressed on thyroid follicular cells, is increased in goiter, and is regulated by thyrotropin through cyclic adenosine 3',5'-monophosphate. (2001) (39)
Effect of hypothyroidism on pituitary cytoplasmic concentrations of messenger RNA encoding thyrotrophin beta and alpha subunits, prolactin and growth hormone. (1986) (38)
Expression of 11β‐hydroxysteroid dehydrogenase in rat osteoblastic cells: Pre‐receptor regulation of glucocorticoid responses in bone (2001) (38)
The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine. (1992) (38)
Free triiodothyronine and free thyroxin in sera of pregnant women and subjects with congenitally increased or decreased thyroxin-binding globulin. (1983) (37)
The effect of thyroid hormones on growth hormone gene expression in vivo in rats. (1987) (37)
Expression of oestrogen receptor and oestrogen‐inducible genes in pancreatic cancer (1997) (37)
The use of a neural network to detect upper airway obstruction caused by goiter. (1998) (36)
An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin production in thyrotropin-secreting pituitary tumors. (1998) (36)
The influence of dexamethasone on serum thyrotrophin and thyrotrophin synthesis in the rat (1989) (35)
Management of acromegaly in Latin America: expert panel recommendations (2009) (34)
Modulation by oestrogen of thyroid hormone effects on thyrotrophin gene expression. (1987) (33)
The Influence of Age and Sex on Tests of Thyroid Function (1985) (32)
Thyroxine replacement treatment and osteoporosis. (1990) (32)
Thyroid hormone, vitamin D and retinoid receptor expression and signalling in primary cultures of rat osteoblastic and immortalised osteosarcoma cells. (1997) (31)
Tissue specific effects of thyroid hormone on 11β-hydroxysteroid dehydrogenase gene expression (1993) (30)
Management of the single thyroid nodule (1992) (30)
Effect of Hypothyroidism and Thyroid Hormone Replacement in Vivo on Pituitary Cytoplasmic Concentrations of Thyrotropin-β and α-Subunit Messenger Ribonucleic Acids* (1987) (30)
Isolation and characterization of human thyroid endothelial cells. (2003) (29)
Estradiol modulates thyroid hormone regulation of the human glycoprotein hormone alpha subunit gene. (1993) (29)
MEASUREMENT OF FREE THYROXINE AND FREE TRIIODOTHYRONINE IN THYROTOXICOSIS AND HYPOTHYROIDISM (1984) (28)
Regulation of type I 5'-deiodinase by thyroid hormone and dexamethasone in rat liver and kidney cells. (1996) (28)
A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. (2014) (28)
Thyroid receptor alpha1 and alpha2 mutations in nonfunctioning pituitary tumors. (1999) (28)
Growth hormone assay standardization: an important clinical advance (2007) (27)
A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro (1987) (26)
Tissue and serum somatostatin-like immunoreactivity in lean and obese Zucker rats. (1980) (26)
DOES GROWTH HORMONE RELEASING FACTOR DESENSITIZE THE SOMATOTROPH? INTERPRETATION OF RESPONSES OF GROWTH HORMONE DURING AND AFTER 10‐HOUR INFUSION OF GRF 1–29 AMIDE IN MAN (1986) (25)
Immunoreactive somatostatin release from rat spinal cord in vitro (1979) (25)
Treatment of amiodarone induced thyrotoxicosis with carbimazole alone and continuation of amiodarone. (1992) (25)
Immunoreactive neurotensin in spontaneous syndromes of obesity and diabetes in mice. (1985) (24)
HORMONAL CONTROL OF GENE EXPRESSION (1988) (24)
Severity of alcoholic liver disease and markers of thyroid and steroid status. (1992) (24)
Thyroid hormone and glucocorticoid regulation of receptor and target gene mRNAs in pituitary GH3 cells (1991) (24)
Regulation of growth hormone secretion and messenger ribonucleic acid accumulation in human somatotropinoma cells in vitro. (1989) (23)
Aspiration cytology of the thyroid. (1987) (23)
Thyrotrophin, forskolin and ionomycin increase cathepsin B mRNA concentrations in rat thyroid cells in culture. (1989) (23)
Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study (2012) (22)
Elevation of free thyroxine measurements in patients without thyrotoxicosis. (1987) (21)
Thyroid-stimulating hormone rapidly stimulates inositol polyphosphate formation in FRTL-5 thyrocytes without activating phosphoinositidase C. (1996) (21)
AMIODARONE AND THYROID HORMONE EFFECTS ON ANTERIOR PITUITARY HORMONE GENE EXPRESSION (1987) (21)
Radioiodine therapy for hyperthyroidism in young patients--perception of risk and use. (1993) (20)
11 beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in the rat colon. (1993) (20)
Radioiodine for hyperthyroidism. (1992) (19)
Serum thyroglobulin and thyroid cancer. (1986) (19)
Inflammatory cytokines and type I 5′-deiodinase expression in Φ1 rat liver cells (1997) (19)
Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis. (1995) (18)
Should serum calcitonin be measured routinely in all patients with nodular thyroid disease? (1995) (18)
Autocrine growth factors produced in the thyroid (1994) (18)
Ultracentrifugation evidence for a somatostatin-binding protein in serum. (1979) (17)
Estrogen Receptor Beta mRNA Expression in Normal and Adenomatous Pituitaries (2004) (17)
Down-regulation of nuclear T3 receptors by thyroid hormones in the rat anterior pituitary (1985) (17)
Clinical application of a sensitive non-isotopic immunometric assay of thyrotropin. (1987) (17)
1 Prolactin and growth hormone (1988) (17)
Calcium/calmodulin regulation of the rat prolactin gene is conferred by the proximal enhancer region. (1991) (17)
Fine needle aspiration cytology in the management of euthyroid goitre. (1987) (16)
The interleukin-1 receptor antagonist gene shows no allelic association with three autoimmune diseases. (1999) (16)
Assessment of a screening process to detect patients aged 60 years and over at high risk of hypothyroidism. (1991) (16)
Administration of stable iodine to the population around the Chernobyl nuclear power plant (1992) (16)
Serum free thyroxine concentrations in normal euthyroid subjects and ones with high serum thyroxine binding globulin concentration. (1983) (16)
Desensitization of rat anterior pituitary gland to thyrotrophin releasing hormone. (1984) (15)
Mortality and hypopituitarism. (1999) (15)
The effect of thyroid hormones in vitro and in vivo on hypothalamic neurotensin release and content. (1983) (15)
Basic and acidic fibroblast growth factor increase prolactin mRNA in a dose-dependent and specific manner in GH3 cells (1995) (15)
PROPYLTHIOURACIL-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS (1989) (15)
The thyroid and osteoporosis (1992) (14)
Phenytoin and thyroid hormone action. (1985) (14)
Stimulation of prolactin secretion by oestradiol in the rat is associated with increased hypothalamic release of thyrotrophin-releasing hormone. (1984) (14)
Characterization of 11 â-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines (1999) (14)
Insulin autoantibodies in Graves' disease--before and after carbimazole therapy. (1990) (13)
Regulation of beta myosin heavy chain, c-myc and c-fos proto-oncogenes in thyroid hormone-induced hypertrophy of the rat myocardium. (1993) (13)
Thyroid hormone response elements in pituitary genes. (1989) (13)
The nervous control of rat somatostatin, glucagon and insulin secretions. (1982) (13)
Neurotensin regulation of TSH secretion in the rat. (1983) (13)
Differential Regulation of the Human Thyrotropin α-Subunit Promoter by Thyroid Hormone Receptors α1 and β1 (1998) (12)
EVALUATION OF A SENSITIVE CHEMILUMINESCENT ASSAY FOR TSH IN THE FOLLOW‐UP OF TREATED THYROTOXICOSIS (1987) (12)
GH and mortality in acromegaly. (2005) (12)
Hormonal regulation of thyrotrophin synthesis and secretion. (1987) (11)
Prolactin and growth hormone. (1988) (11)
Apoptosis during goitre involution - the role of Bcl-2. (2000) (11)
Thyroxine replacement therapy (1991) (11)
The effect of propranolol on circulating thyroid hormone measurements in thyrotoxic and euthyroid subjects. (1985) (11)
Thyroid status affects the regulation of prolactin mRNA accumulation by tri-iodothyronine and thyrotrophin-releasing hormone in cultured rat anterior pituitary cells. (1987) (11)
Modulation of epidermal growth factor binding and receptor gene expression by hormones and growth factors in sheep pituitary cells. (1994) (11)
Regulation of α and thyrotrophin-β subunit mRNA levels by androgens in the female rat (1990) (11)
Regulation of α- and β-myosin heavy chain messenger RNAs in the rat myocardium by amiodarone and by thyroid status (1989) (11)
Control of thyroglobulin secretion from the rat thyroid gland. (1984) (11)
The value of imaging in the diagnosis of thyroid cancer. (1992) (10)
Tissue distribution of immunoreactive somatostatin in the South African clawed toad (Xenopus laevis). (1979) (10)
The effect of neurotensin on pituitary secretion of thyrotrophin and prolactin in vitro. (1984) (10)
Prevalence and clinical usefulness of thyroid antibodies in different disease states of the thyroid (1999) (10)
Limitations of a sensitive assay for thyrotropin in managing patients with thyroid disease. (1988) (10)
DEXAMETHASONE‐SUPPRESSIBLEHYPERALDOSTERONISM: STUDIES ON OVERPRODUCTION OF 18‐HYDROXYCORTISOL IN THREE AFFECTED FAMILY MEMBERS (1988) (10)
Differential regulation by thyroid hormones of myosin heavy chain α and β mRNAs in the rat ventricular myocardium (1989) (10)
Hormone-induced changes in nuclear receptor stoichiometry in HL60 cells correlate with induction of monocyte or neutrophil differentiation. (1998) (9)
Effect of hypothyroidism and thyroid hormone treatment of the rat on hepatic Spot 14 and thyroxine binding prealbumin mRNAs. (1989) (9)
HLA CLASS II DNA GENOTYPES IN GRAVES' DISEASE: CLUES TO INHERITANCE OF THE HLA‐LINKED COMPONENT OF SUSCEPTIBILITY (1988) (9)
Demonstration of thyrotrophin beta-subunit messenger RNA in rat pituitary cells in primary culture--evidence for regulation by thyrotrophin-releasing hormone and forskolin. (1986) (9)
Regulation by thyroid status of c-myc, c-fos and H-ras mRNAs in the rat myocardium. (1991) (9)
Effect of hypothyroidism and thyroid hormone replacement in vivo on pituitary cytoplasmic concentrations of thyrotropin-beta and alpha-subunit messenger ribonucleic acids. (1987) (9)
Measurement of free thyroid hormones in patients on long-term phenytoin therapy (2004) (9)
THYROID HORMONES IN NON‐INSULIN‐DEPENDENT DIABETES BEFORE AND AFTER DIETARY TREATMENT (1983) (8)
Localization in and release of somatostatin from brain and gut. (1979) (8)
Measurement of serum TSH in the investigation of patients presenting with thyroid enlargement. (1998) (8)
Phorbol esters showing selective activation of PKC isozymes in vitro regulate thyroid function and insulin-like growth factor binding protein secretion. (1994) (8)
Abnormalities of thyroid function tests in hospital inpatients. (1985) (8)
Transrenal gradient of serum somatostatin-like immunoreactivity in the rat. (1978) (8)
In vitro release of cholecystokinin octapeptide-like immunoreactivity from rat brain synaptosomes. (1981) (8)
Pituitary imaging is essential for women with moderate hyperprolactinaemia. (1993) (8)
Changes in the kinetics of inositol transport during TPA‐induced differentiation of HL60 cells towards monocytes (1991) (7)
Pasireotide LAR vs octreotide LAR in patients with acromegaly: double-blind, crossover, extension period to a randomized, double-blind, multicenter, phase III study (2012) (7)
13 Thyroid nodules and thyroid cancer—diagnostic aspects (1988) (7)
Switching Patients with Acromegaly from Octreotide LAR to Pasireotide LAR Improves Biochemical Control: Crossover Extension to a Randomized, Double-Blind, Multicenter, Phase III Study (2013) (7)
Amiodarone and thyroid dysfunction (1993) (7)
The critical parameters in GH excess. (2005) (7)
THYROXINE‐BINDING PREALBUMIN GENE POLYMORPHISM: A POPULATION STUDY (1990) (7)
Calcium dependence of prolactin mRNA accumulation in GH3 rat pituitary tumour cells. (1988) (7)
Thyroid Receptor a 1 and a 2 Mutations in Nonfunctioning Pituitary Tumors* (1999) (7)
Thyrotrophin gene regulation. (1988) (7)
Modulation of thyrotrophin release from an intracellular pool by pre-exposure to thyrotrophin-releasing hormone and dibutyryl cyclic AMP. (1986) (6)
IS OLEIC ACID THE THYROXINE BINDING INHIBITOR IN THE SERUM OF ILL PATIENTS? (1989) (6)
Regulation of myo-inositol transport during the growth and differentiation of thyrocytes: a link with thyroid-stimulating hormone-induced phospholipase A2 activity. (1995) (6)
Sharing of susceptibility loci between autoimmune diseases: lack of association of the insulin gene region with Graves' disease. (1999) (6)
Prevalence of gallstones in acromegalics untreated with somatostatin (1993) (6)
Comparison of the short ACTH stimulation test with the insulin tolerance/glucagon test (1998) (6)
Using an increased fixed dose of 131 I (600MBq) leads to improved outcome in patients with hyperthyroidism (2007) (6)
Thyroid and steroid hormone regulation of proto-oncogene expression (1989) (6)
Goitre and thyroid cancer (2001) (5)
Neurotensin release from rat hypothalamus in vitro. (1983) (5)
Effect of triiodothyronine treatment on thyrotrophin β- and α-messenger RNAs in the pituitary of the euthyroid rat (1988) (5)
3,5‐DIIODOTYROSINE AND THYRONINE IN THE URINE OF PATIENTS WITH CHRONIC RENAL DISEASE (1986) (5)
Multiple DNA elements determine basal and thyroid hormone regulated expression of the human glycoprotein alpha subunit gene in pituitary cells. (1990) (5)
Basic Fibroblast Growth Factor Is an Autocrine Factor for Rat Thyroid Follicular Cells (1991) (5)
The Network for the Enhancement of Endocrinology and Oncology Knowledge: a case-based consideration of current practice in Cushing's disease and acromegaly. (2009) (5)
Treatment options for acromegaly. (1996) (5)
Substance P release from rat hypothalamus and spinal cord. (1980) (5)
DNA and RNA analysis of cytochrome P-450 21-hydroxylase: transcriptional activity in congenital adrenal hyperplasia. (1988) (5)
The structure of the human thyroxine binding globulin (TBG) gene. (1993) (5)
Mechanisms of TSH release: studies with forskolin, phorbol ester and A23187 (1987) (4)
Characterization of immunoreactive somatostatin released from rat nervous system in vitro. (1982) (4)
Growth hormone therapy does not induce cancer (2006) (4)
Evidence for the use of igf-I as a predictor of mortality in acromegaly is lacking. (2004) (4)
Inflammatory cytokines and type I 5'-deiodinase expression in phi1 rat liver cells. (1997) (4)
A RADIOIMMUNOASSAY FOR NEUROTENSIN (1981) (4)
Glycosylation of human thyroglobulin and characterization by lectin affinity electrophoresis. (1986) (4)
The role of growth hormone-receptor antagonism in relation to acromegaly (2004) (4)
Regulation of TSH gene transcription (1986) (4)
Atrial fibrillation predicts mortality in thyrotoxicosis (2002) (4)
Human Pituitary Tumors in Cell Culture: Modulation of Prolactin and Growth Hormone Messenger RNA Levels in Vitro (1989) (4)
Is cyclical bowel habit mediated by female sex hormones? (1994) (4)
A modulatory role for cyclic AMP in the control of thyrotrophin release: studies with forskolin and dibutyryl cyclic AMP. (1986) (3)
RADIOIODINE FOR HYPERTHYROIDISM : PERHAPS THE BEST OPINION (1992) (3)
Regulation of alpha and thyrotrophin-beta subunit mRNA levels by androgens in the female rat. (1990) (3)
Follow-up of treated acromegaly: similarities and differences in assessing the response to different primary treatment modalities. (2000) (3)
MEASUREMENT OF FREE THYROXINE AND FREE TRIIODOTHYRONINE IN ASYMPTOMATIC SUBJECTS WITH HIGH CONCENTRATIONS OF SERUM TSH AND A HISTORY OF RADIOIODINE THERAPY (1984) (3)
Thyroid autocrine factors: regulation of secretion of insulin-like growth factor binding proteins from sheep thyroid cells by autocrine basic fibroblast growth factor. (1991) (3)
Thyroid hormone regulation of human pituitary alpha subunit gene expression. (1992) (3)
New Treatments for Acromegaly (1998) (3)
Suppression of prolactin release and mRNA accumulation by two novel dopamine agonist agents. (1989) (3)
The effects of ethanol, 3,5,3'-triiodothyronine (T3) and oestradiol (E2) on thyroid hormone nuclear receptor expression in human hepatocyte primary cultures. (1995) (3)
Sodium dependent inositol transport in HL60 cells is not related to Na+/K+, ATPase activity (1991) (2)
Nuclear proteins from the rat pituitary gland bind to regulatory sequences of the thyrotrophin-beta gene. (1989) (2)
The use of a multiwire camera for the detection of 3H labelled cDNA/mRNA hybrids. (1987) (2)
And the sun stood still (1990) (2)
Cathepsin B in the rat thyroid FRTL5 cell line (1986) (2)
Oestrogen receptor, progesterone receptor, ERD5 and PS2 expression in normal pancreas and pancreatic cancer (1995) (2)
Use of Long-Acting Somatostatin Analogs in Treating Acromegaly (1995) (2)
Differential regulation of the human thyrotropin alpha-subunit promoter by thyroid hormone receptors alpha1 and beta1. (1998) (2)
Thyroid nodules and thyroid cancer--diagnostic aspects. (1988) (2)
Growth hormone--from molecule to mortality. (2004) (2)
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study (2015) (1)
Differential regulation by thyroid hormones of myosin heavy chain alpha and beta mRNAs in the rat ventricular myocardium. (1989) (1)
Gender, age, goitre type and serum TSH level predict thyroid neoplasia in 1500 patients with thyroid enlargement investigated by FNAC (2004) (1)
Characterization of purified rat thyroglobulin and thyroglobulin secreted by FRTL-5 cells (1986) (1)
Thyrotrophin receptor expression: does it help in assessing the prognosis of thyroid cancer? (1993) (1)
Frequency of the Euthyroid Sick Syndrome (1985) (1)
Cardiac autonomic function in hyperthyroidism (2003) (1)
Radioiodine Therapy for Hyperthyroidism and Risk of Malignancy (1990) (1)
β-Blockade and Serum Triiodothyronine (1984) (1)
Heparin-induced thrombosis. (1997) (1)
Effect of triiodothyronine treatment on thyrotrophin beta- and alpha-messenger RNAs in the pituitary of the euthyroid rat. (1988) (1)
Thyroid Function after Myocardial Infarction (1984) (0)
Heparin and inflammatory b o wel disease (1999) (0)
Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study (2013) (0)
Association between serum insulin-like growth factor-1 and serum growth hormone levels across an oral glucose tolerance test in assessing disease activity in acromegaly (2004) (0)
Monitoring acromegaly disease activity with growth hormone and insulin like growth factor-I in 501 patients (2008) (0)
Primary medical therapy for acromegaly (2003) (0)
Effect of ACTH deficiency and hydrocortisone replacement dose on mortality in patients with acromegaly (2009) (0)
Differential regulation of the ghrelin promoter in WRL68 and HEK293 cells (2003) (0)
The Significance of TSH Values Measured in a Sensitive Assay in the Follow-Up of Hyperthyroid Patients Treated With Radioiodine (1993) (0)
Pituitary tumor transforming gene and basic fibroblast growth factor-2 - novel potential molecular indicators for thyroid cancer (2002) (0)
The SH3 domain of PTTG differentially mediates FGF-2 transactivation and cell transformation (2002) (0)
Thyroxineprescription inthecommunity: serum thyroidstimulating hormone levelassaysas an indicatorof undertreatmentor overtreatment (1993) (0)
Effect of radiotherapy and pituitary dysfunction on mortality in patients with acromegaly (2008) (0)
491 Association between serum thyroid hormone concentrations and occurrence of atrial fibrillation in a large community-based population of elderly subjects (The Birmingham Elderly Thyroid Study) (2005) (0)
Molecular Cloning of Human Transthyretin: Subunit Assembly Occurs within the Endoplasmic Reticulum (1987) (0)
Neurotensin in the brain, intestine and pancreas of ob/ob and db/db mice (1984) (0)
Predictors of response to medical therapy in patients with acromegaly (2008) (0)
Sodium-iodide (NIS) gene expression is a potential prognostic indicator for thyroid cancer and is inhibited by pituitary tumor transforming gene (PTTG) (2003) (0)
Thyroid Stimulating Hormone (TSH) and Triiodothyronine (T3) May Interact in Regulating Thyroglobulin (TG) Release (1985) (0)
Distinct Actions of Thyroid Hormone Receptor α and β in Osteosarcoma Cells: Implications for the Role of T, in Bone Development (1994) (0)
Characterization of 11â-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines (1999) (0)
The Effect of Dietary Treatment in Non-Insulin Dependent Diabetes (1981) (0)
Introduction - chernobyl irradiation and thyroid cancer (2005) (0)
Comment on: Monitoring the response to treatment in acromegaly. Author's reply (2005) (0)
Thyroid Hormones Regulate Growth Hormone and Prolactin Gene Expression in Vivo (1986) (0)
Effects of Hyper- and Hypothyroidism on Hypothalamic Peptide Concentrations (1983) (0)
Acromegaly - improving outcomes (2012) (0)
The Birmingham Elderly Thyroid Study (BETS): TSH and fT4 values in 5784 community-living subjects aged 60 and over (2005) (0)
Assessment of Thyroid Neoplasia (2009) (0)
thyroxine therapy and thyrotoxicosis . Cardiac hypertrophy as a result of long-term (2003) (0)
Control of TSHβ and α Subunit Gene Expression by Thyroid Hormone (1986) (0)
Glycosylation of Human Thyroglobulin-Characterization by Lectin Affinity Electrophoresis (1986) (0)
Association between serum TSH concentrations and occurrence of atrial fibrillation in a large community-based population of elderly subjects (2005) (0)
P1-27: Absolute value of free thyroxine predicts atrial fibrillation in relation to age and sex in elderly subjects (2006) (0)
Disruption of the SH3 domain of pituitary tumor transforming gene (PTTG) reveals distinct mechanisms of FGF-induction and cell transformation (2002) (0)
Tissue somatostatin immunoreactivity in gold thioglucose treated mice. (1980) (0)
A potential role for human securin/PTTG in the developing human fetal brain (2003) (0)
Radioiodine for hyperthyroidism: Authors' reply (1992) (0)
Association between serum thyrotropin concentrations and occurrence of atrial fibrillation in a large community-based population of elderly subjects (the Birmingham elderly thyroid study) (2005) (0)
A Central Role for Angiopoietins in Goitre Formation (2000) (0)
Serum Free and Total Thyroxine (T4) and 3,5,3,1 Triiodothyronine (T3) Levels in Insulin Dependent Diabetics: Influence of Diabetic Metabolic Control (1983) (0)
Bartonella henselae in inflammatory bowel disease (2001) (0)
Failure of somatostatin to inhibit epinephrine (adrenaline)-stimulated hepatic glucose output in vitro. (1980) (0)
Inhibition of 11beta-HSD2 has an anti-proliferative effect on pituitary tumour cells (2002) (0)
Faculty Opinions recommendation of Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. (2007) (0)
Thyroid surgery in an otolaryngology department (1997) (0)
Cardiac hypertrophy asaresult oflong-term thyroxine therapy andthyrotoxicosis (1996) (0)
Mortality in elderly patients with subclinical hyperthyroidism (2002) (0)
Characterization of Thyroglobulin in Fluid Aspirated from Thyroid Cysts (1984) (0)
Premature mortality and hypopituitarism - Authors' reply (2001) (0)
Optimisation of Camp Response of FRTL-5 Cells to Thyroid Stimulation (1986) (0)
Serum Free Thyroxine (T4) and Free 3,5,3′ Triiodothyronine (T3) Concentrations in Pregnancy and in Subjects with Congenitally Raised Thyroxine Binding Globulin (TBG) (1983) (0)
Tissue thyrotoxicosis (1985) (0)
Outcomes in acromegaly: A retrospective study of 419 patients from the West Midlands region of the United Kingdom (2003) (0)
Mortality in elderly patients with subclinical hyperthyroidism [4] (multiple letters) (2002) (0)
Anaplastic carcinoma of the thyroid presenting with hyperthyroidism (2002) (0)
Persisting atrial dysrhythmis in treated thyrotoxicosis- the cause of excess vascular mortality? (2001) (0)
Prolactin and TSH Responses to TRH of Perifused Hypothyroid and Euthyroid Rat Anterior Pituitaries (AP) in Vitro (1983) (0)
Therapeutic progress--review VII. The medical treatment of Paget's disease. (1983) (0)
Characterisation of thyroid hormone (T3) receptors (T3R) in primary cultures of rat calvarial osteoblasts (1995) (0)
21α Hydroxylase Transcriptional Activity in Congenital Adrenal Hyperplasia (CAH) (1987) (0)
Expression of ventricular proto-oncogenes in three models of cardiac hypertrophy (1990) (0)
Pituitary Tumor Transforming Gene (PTTG): A Multifunctional Oncogene in Endocrine Neoplasia (2003) (0)
Ghrelin inhibits proliferation of breast cell lines acting via the growth hormone secretagogue receptor (GHS-R) (2002) (0)
Differential Effect of Oestradiol on Rat Thyrotrophs and Lactotrophs (1984) (0)
The destruction box of pituitary tumor transforming gene (PTTG) mediates cell transformation (2002) (0)
Regulation of alpha- and beta-myosin heavy chain messenger RNAs in the rat myocardium by amiodarone and by thyroid status. (1989) (0)
Expression and function of vascular endothelial growth factor (VEGF) and its receptor KDR in pituitary tumours (2002) (0)
Association between serum TSH and fT4 concentrations and occurrence of atrial fibrillation in a large community-based population of elderly subjects. The Birmingham Elderly Thyroid Study (BETS) (2005) (0)
Cellular Aspects of Thyroid Hormones (1989) (0)
Mortality in elderly patients with subclinical hyperthyroidism. Authors' reply (2002) (0)
Letter re: Monitoring the response to treatment in acromegaly. (2005) (0)
Factors associated with response to medical therapy in patients with Acromegaly (2008) (0)
Abnormalities ofthyroid function tests inhospital inpatients (1985) (0)
Thyroid Hormone Binding to Rat Anterior Pituitary Nuclear Receptors (1985) (0)
Outcome of atrial fibrillation complicating hyperthyroidism (2004) (0)
Comparison of Thyroglobulin Glycosylation in Normal, Adenomatous and Carcinomatous Thyroid Tissue (1986) (0)
PDB54 ASSESSING THE BURDEN OF ACROMEGALY: A REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND ECONOMICS (2009) (0)
426 Oestradiol-stimulated prolactin secretion: role of thyrotrophin releasing hormone (TRH) (1983) (0)
Expression of fibroblast growth factor and its receptor in thyroid hyperplasia and neoplasia (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael C. Sheppard?

Michael C. Sheppard is affiliated with the following schools:

University of Birmingham